Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
OTC Markets lists LHA Advisors, Inc. as the investors relations contact for PROT.
but on LHA Advisors website they have a list of all their current and former clients and theres no mention of Proteonomix.
I contacted LHA Advisors to see what thats about and it seems like they've never heard of Proteonomix OR Stromacel.
They gonna revive this for the liver damage coming from WuFlu?
Any idea what is propelling PROT today?
nah, somebody sneezed and some change fell out of their pocket.
Cohen was run off. No one is at the helm.
nothing will happen. absolutely nothing.
Just checked the clinical trials website and looks like our phase 2 trial was just updated in May. Wonder what will happen with this...?
Plerixafor for Stem Cell Mobilization in Normal Donors
This study is ongoing, but not recruiting participants.
Sponsor:
M.D. Anderson Cancer Center
Collaborator:
Proteonomix, Inc.
Information provided by (Responsible Party):
M.D. Anderson Cancer Center
ClinicalTrials.gov Identifier:
NCT01818284
First received: March 21, 2013
Last updated: May 4, 2015
Last verified: May 2015
Do you happen to have a copy of or a link to his bankruptcy filing?
You are exactly correct. Looking back with 20/20 hindsight it is pretty clear to see. Going back to the "pinks" to keep from being reporting compliant was a big red flag. I commented at the time that that was not in the best interest of shareholders, but alas, I still liked the story and hung on. The whole GXG story stunk and was clearly another huge red flag. The ongoing "liver trial" froze me in place. Even though I didn't like the GXG story I held in hope that the liver trial would be the cure of all the stock ill's. Cohen knew exactly what he was doing with the liver trial story. He clearly should be in jail, but as I have said, white collar crime is the way to go in this country. Rob a convince store and you go to jail for 5-7 yrs. Rob a couple of thousand share holders and you get a slap on the wrist.
That's the sanction on the Administrative hearing only. There is also a criminal hearing which he plead guilty to. He will have a disgorgement penalty but the amount hasn't been determined.
See link: https://www.sec.gov/litigation/litreleases/2015/lr23238.htm
I was barking the entire time how this spin-off and GXG listing had gaping holes in its story and how parts made little sense. And people on the board like Sheeple kept defending the transaction and how we would all get our shares. Well, what we all got was screwed! Man oh man, Cohen carefully planned this out if you think about it. Starting when the Company opted to go back on the Pinks so he wouldn't have to be "reporting compliant". We were all so excited about the trials at the time, no one cared...but in the back of my mind I heavily questioned it. Thankfully, I sold a lot of my shares at much higher prices but I was definitely left holding the proverbial "bag" on a bunch! Oh well, maybe we will all see some money back once the SEC is done with him, too bad he appears broke with his latest BK filing!
again, not much. gotta know when to get out!!!!
So what we see here is that the story about splitting the shares and forming a new company and moving to GXG exchange was a rouse to pump up the share price after Cohen had distributed shares to himself and family members, so he could sell them on the open market and pocket the money.
For that he gets a slap on the wrist and an order to stay away from penny stocks in the future.
All investors in PROT get left holding an empty bag. Got to love those pink sheet companies. White collar crime does pay. He declares bankruptcy so the gov. can't come after his home and personal assets.
PROT: SEC Admin Proceeding against CEO:
http://www.sec.gov/litigation/admin/2015/33-9745.pdf
On the Gov. site the liver trial has not been updated in over two years. It really looks dead. It is true that M.D. Anderson did update their site in Sept 14. It is hard to see how that will help PROT going forward. The company is broke, Cohen is out the door, Fiddler is gone. I think the MD Anderson trial does not end until 2018. I think McNeece is still at MD Anderson, but if he wants to keep his reputation I'm sure he will stay away from this company. Wish I had.
The trials are real and ongoing. One in Houston at MD Anderson and one at Rutgers in New Jersey. There are links on this board a few posts down. However, I doubt (now) we will ever see anything come back to us from that whole spin off GXG fiasco....now that Cohen has plead guilty, it's finally over for me.
There is no reason to believe that we are going to receive shares. Cohen has been proven to be a liar and a cheat.
PROT's name has been removed from the GXG. Nothing came of that story, (by the way, they did not take it private. The story was that it would be listed on the GXG). If the liver trial was legit it would have been completed well over a year ago. Nothing came of that story.
PROT was a penny stock sham. We were had.
When are we going to say 'welcome back' on PROT?
They took the stem cell IP of the company private. We are awaiting our shares in the private company.
The SEC will not have jurisdiction. The publicly traded PROT, however, may well be dead.
But he is gone:
Yes, feel free to move on.
Oh please. Let's face the facts. The man is a fraud and a crook. No wonder he filed for bankruptcy. The liver trials came to nothing. The splitting of shares into two companies was a fraud. I said a long time ago that we have been had.
Time to face it.
I wish they'd have given him jail time. Not that it would recoup any of our money. White collar crime rarely means jail time in this country unless you steal on the order of Enron. He pays the SEC a fine and we loose all our money.
Sad, but time to move on.
Thank you Renee for the post. Now we know.
On the bright side, this is about shuffling shares around and not falsifying the clinical trial reports.
PROT: SEC Charges New Jersey Biotechnology Company and Its Chief Executive Officer with Securities Fraud:
http://www.sec.gov/litigation/litreleases/2015/lr23201.htm
http://www.sec.gov/litigation/complaints/2015/comp23201.pdf
This, as I understand it, is a personal BK. I would assume that the CEO is just covering all bases, and is still confident that the company's clinical trials will produce enough interest to make us some real money.
Curious as to why such a large bid size for the PROT shares.
That is what I have gathered from these PRs, the dates and contents of which supercede any and all claims on the company's various out-dated sites and PRs.
http://ih.advfn.com/p.php?pid=nmona&article=55748215
http://ih.advfn.com/p.php?pid=nmona&article=56975867
I wish I cold invest in the Proteoderm cosmeceuticals but it seems like the company's growing pains proved fatal for this subsidiary. So much demand before they could get manufacturing or inventory off the ground. I am guess it is due to the fact that Matrix NC-138 only received approval for US commericalization years after their fad peaked.
http://www.marketwired.com/press-release/proteonomix-inc-prot-announces-receipt-first-order-purchase-proteoderms-stem-cell-derived-1227288.htm
http://finance.yahoo.com/news/proteonomix-inc-prot-announces-subsidiary-210000465.html
Have any of the early investors here, prior to January 2013, received their shares for the private BVI corporation?
It seems like the litigation settlement in April 2013 was completed as reparations for the failure of the BVI shares to be distributed... otherwise why would they do it?
I was quite intrigued by this stock's story at the start of my research. A biotech company with active clinical trials trading for 0.01 and, assuming no recent and unreported dilution, under $100K market cap!?
I was especially interesting the in cosmoceutical subsidiary, Proteoderm. But alas, it seems that the rights/ownership of Proteoderm have been transferred to a private holding company.
RIP PROT
I agree. I think that is a plausible timeline.
Here's another option to try and dig up some info...contact The MD Anderson Cancer Center and talk to them about the progress of the on-going trial that was recently verified - here's the info to do so:
Please refer to this study by its ClinicalTrials.gov identifier: NCT01818284
Contacts
Contact: Chitra M. Hosing, MD 713-792-8750
Locations
United States, Texas
University of Texas MD Anderson Cancer Center Recruiting
Houston, Texas, United States, 77030
Sponsors and Collaborators
M.D. Anderson Cancer Center
Proteonomix, Inc.
Investigators
Principal Investigator: Chitra M. Hosing, MD M.D. Anderson Cancer Center
WM
Also, here is a link to the last 8K they filed and as you will see there are several financial institutions that owned hefty amounts of PROT stock. Maybe contacting them will help get to the bottom of what is going on??
http://www.sec.gov/Archives/edgar/data/1469559/000104118312000014/f8kunrergisteredsalesdisclos.htm
WM
Here is a link that will take you to all the major share holders on file with their contact information. Perhaps trying to contact some of the other individuals who were involved with this might give us a clue as to what is going on? The last filing with the SEC was back in 2012 so these addresses might be outdated but hey it could be worth a shot...I would start with Ian McNiece....
http://www.sec.gov/cgi-bin/own-disp?action=getissuer&CIK=0001469559
WM
I have no idea what is going on with Cohen personally, as I have never talked to him. I am more interested in the two clinical trials. Maybe he is trying to settle his debts before anything actually happen to the price of the stock.
10m o/s, $.012, 120k market cap, many patents and two clinical trials?
This looks extreme undervalued. Hopefully we will hear something soon.
I would expect some updates to be done by the end of the first quarter.
Has anyone checked on the status of either of the clinical trials?
I do not think there are any assets, other than the intellectual property. And if the IP is worth something, then we already have a winner, when the trials are completed.
I hope somebody knows a name of a good lawyer...Class action wise..
That information has not been updated in quite some time. Not sure how to do this, but we need to keep our eyes on the clinical trials. Any thoughts on how to accomplish that?
The phone number listed on that website is no longer in service and the email address bounces back....
WM
I guess the truth hurts, another 0 volume day
LMAO, look at the little chart above that says 0 volume, that's all the DD anybody needs. Too funny
Look a little harder.
Please give me the details on your DD. Any DD would have shown that the value is not with the ticker symbol PROT (Stromacel), but actually the spin off, which is where the clinical trials are going on. Could explain why everyone other than a few know why this ticker symbol does not trade much. Again, I would love to see your DD. giggle, chuckle, and kaboom.
Not much of a website, but the Stromacel website is still up, which is the name of this public entity. Prot still has the trials ongoing, there is still a pulse...imo
http://stromacel.com/
DD is telling me this POS is a scam, they cant even pay for the web site. What a clown show
Anyone notice when the website went down? Looks like according to the WhoIs database it was updated this past May and is still registered to Michael Cohen. I tried calling the numbers listed on the registration and they are no longer working numbers. I have been holding out on this one hoping for a miracle but it now seems as though this was officially a scam. Company claims that it has been in business since 1995 but only registered its website in 2008 right before the pump started and we don't even have a website. According to the MD Anderson Cancer Center we do still have an active phase 2 trial going but since we never heard anything about the phase 1 trial which was supposed to be completed in September of 2013 I am not holding my breath that we will ever hear anything about our phase 2.
WM
Followers
|
53
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
3720
|
Created
|
07/17/06
|
Type
|
Free
|
Moderators |
Company Information:
187 Mill Lane
Mountainside, NJ 07092
Phone: 973-544-6116
Fax: 973-833-0277
E-mail: info@proteonomix.com
CIK: 0001469559
1. Through our operating subsidiary, National Stem Cell, we have developed a catalog of intellectual properties and patent applications. These technologies are designed to work together in a synergistic fashion. Our initial focus in stem cell therapeutics is to achieve a leadership position in:
We need to test its technologies and therapies before commercialization.
We have identified stem cells in the human pancreas and have applied for patents for cell surface markers (the molecules present on the surface of each cell which define the cell on what receptors are present - a technique often used to associate cells with certain immune functions) for these pancreatic stem cells as well as methods for their isolation. Based on the fact that these cells are autologous (from same person) rather than from a non-related donor, we anticipate that the cells that we are able to isolate will substantially reduce rejection when transplanted into the liver of the same diabetic patient. The company is performing further research in this area with the University of Miami.
2. Through National Stem Cell, we have developed a patent-pending container device for cryopreservation of stem cells (the process where cells are preserved by cooling to low sub-zero temperatures) that we believe will provide significant improvements in viable cell recovery and contaminant protection, both in freezing and thawing stem cells, than is found with cryostorage containers currently in use.
3. Multiple cosmetic products have been developed. The products are based on our patents describing our Secreted Matrix TM technology. These products are in production and their launch is scheduled for the beginning of 2010.
4.Laboratory services are provided by our wholly owned, accredited and operating reproductive cell/tissue banking service (sperm, ova, ovarian tissue, testicular tissue and embryos). It is anticipated that our laboratory services will provide advanced technologies and procedures for the collection, laboratory testing, bio-genetic typing, processing and cryogenic storage of stem cells from both umbilical cord and peripheral blood. Umbilical cord blood stem cells and reproductive cells are processed and banked for both allogeneic (transfer from one person to another) and autologous (derived from and used by the same individual) therapeutic transplantation for a variety of medical disorders, including leukemia and lymphoma with stem cells and infertility with sperm cells. We have developed and implemented a unique, effective and comprehensive strategy for the marketing of our services and products on a national and international scale for applications in stem cell therapeutics together with cell-tissue laboratory services.
Management:
Steven Byle, Secretary |
Important Company Highlights:
Proteoderm, our latest product.
Recent News:
http://www.pinksheets.com/pink/quote/quote.jsp?symbol=prot
News of particular importance:
November 11, 2011 @4:00 PM
Proteonomix, Inc. (PROT) Announces That Its Subsidiary Proteoderm, Inc. Has Received the Approval of Its Application for INCI...
Michael Cohen, President of the Company, stated: "The approval of the CIR and its issuance of an INCI name to our Matrix NC-138 is a significant and momentous occasion. We have now demonstrated that we are committed to develop and deliver to the market safe and innovative products. The issuance of the INCI name will allow the company to move forward with commercialization of our cosmeceutical product, Proteoderm NC-138 in the USA."
Proteoderm Inc. has developed a line of anti-aging skin care cosmetics based on its research with stem cell derivatives. We are the first company to use a matrix of proteins ("Matrix NC-138") originally discovered in non-embryonic stem cells, to harness the anti-aging potential in cosmeceutical products.
Mr. Cohen continued: "We anticipate that our efforts to market the product and partner up with other cosmetic manufacturers will be greatly enhanced by the issuance of an INCI name."
Based in Washington, D.C., the Personal Care Product Council ("PCPC") has funded the Cosmetic Ingredient Review ("CIR") Expert Panel as an independent, nonprofit panel of scientists and physicians established in 1976 to assess the safety of ingredients used in cosmetics in the U.S. with the support of the U.S. Food and Drug Administration and the Consumer Federation of America in an open, unbiased, and expert manner, and to publish the results in the peer-reviewed scientific literature. The CIR mission is to review and assess the safety of ingredients used in cosmetics in an open, unbiased, and expert manner, and to publish the results in the peer-reviewed scientific literature. Upon conclusion of its review the CIR issues an International Nomenclature of Cosmetic Ingredients ("INCI") name to the ingredient. The PCPC does not regulate but provides information on national and international regulation. We presently adhere to the Personal Care Products Council Consumer Commitment Code, including filing timely reports with the FDA regarding manufacturing and ingredient usage.
Feb 18, 2010 08:30 ET
Proteonomix, Inc. (PROT) Announces the Formation of StromaCel, Inc.
Proteonomix, Inc. (PINKSHEETS: PROT) announces that it has formed a wholly-owned subsidiary, StromaCel, Inc.
The mission of StromaCel is to develop therapies using stromal cells. Stromal cells are key components of tissues and provide critical cytokines and growth factors as well as the cellular microenvironment for normal homeostasis. A cytokine is a small protein released by cells that affects the interactions and communications between cells and the behavior of cells. A growth factor is a naturally occurring substance capable of stimulating cellular growth, proliferation and differentiation. Homeostasis is a self-regulating process by which a biological system maintains stability while adjusting to changing conditions. Stromal cells provide a niche proliferation environment for stem cells.
StromaCel's goal is to study the basic cellular properties of stromal cells and to identify the utility of cellular and protein derivatives in disease repair.
StromaCel is the fifth subsidiary of Proteonomix. National Stem Cell, Inc. is Proteonomix' operating subsidiary. The Sperm Bank of New York, Inc., engaged in reproductive tissue banking, including sperm, ova, ovarian tissue and testicular tissue, is a subsidiary of National Stem Cell, Inc. Proteoderm has developed and has begun to manufacture and distribute a line of anti-aging cosmeceuticals based on stem cell derivatives. Proteonomix Regenerative Translational Medicine Institute, Inc. ("PRTMI") intends to focus on the translation of promising research in stem cell biology and cellular therapy to clinical applications of regenerative medicine. Going forward, Proteonomix intends to create and dedicate a subsidiary to each of its technologies.
Proteonomix is a biotechnology company focused on developing therapeutics based upon the use of human cells and their derivatives. Proteonomix has facilities at a number of academic institutions. Please visit www.proteonomix.com, www.proteoderm.com, www.pinksheets.com and www.sec.gov for further information about the Company.
Certain statements contained herein are "forward-looking" statements (as defined in the Private Securities Litigation Reform Act of 1995). Proteonomix, Inc. cautions that the statements made in this press release relating to the mission statement of StromaCel constitute forward-looking statements and makes no guarantees of future performance and actual results or developments may differ materially from projections in forward-looking statements. Forward-looking statements are based on estimates and opinions of management at the time the statements are made.
Filings:
Transfer Agent:
Olde Monmouth Stock Transfer Co., Inc.
200 Memorial Pkwy
Atlantic Highlands 07716
Share Structure:
Outstanding Common Shares
7,910,556 | a/o August 20, 2012 |
Float
5,155,665 as of Nov 4, 2011
Authorized Shares
240,000,000 as of Nov 4, 2011
Investor Relations:
All messages, including iBox content, are the opinion of the posters, are no substitute for your own research, and should not be relied upon for stock trading or any other purpose.
Also, keep in mind that moderators may or may not have a position in said stock. Being a moderator isn't a sign of endorsement.
Please keep your posts on topic because your message(s) will probably be deleted when:
* Posting content that's off-topic to the subject of this board;
* Posting statements that don't add value to the discussion; or
* When you violate any other posting term of the iHub User Agreement: http://investorshub.advfn.com/boards/complex_terms.asp
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |